These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12115546)

  • 1. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.
    Steketee K; Timmerman L; Ziel-van der Made AC; Doesburg P; Brinkmann AO; Trapman J
    Int J Cancer; 2002 Jul; 100(3):309-17. PubMed ID: 12115546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
    Duff J; McEwan IJ
    Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
    Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer.
    Southwell J; Chowdhury SF; Gottlieb B; Beitel LK; Lumbroso R; Purisima EO; Trifiro M
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):138-46. PubMed ID: 18619542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors.
    McDonald S; Brive L; Agus DB; Scher HI; Ely KR
    Cancer Res; 2000 May; 60(9):2317-22. PubMed ID: 10811100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
    Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
    Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
    Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
    Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
    Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
    Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
    Bergerat JP; Céraline J
    Hum Mutat; 2009 Feb; 30(2):145-57. PubMed ID: 18800375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
    Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
    Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
    J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
    Zhou J; Liu B; Geng G; Wu JH
    Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.
    Moehren U; Papaioannou M; Reeb CA; Grasselli A; Nanni S; Asim M; Roell D; Prade I; Farsetti A; Baniahmad A
    FASEB J; 2008 Apr; 22(4):1258-67. PubMed ID: 17991730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
    Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J
    Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.
    Yang CS; Xin HW; Kelley JB; Spencer A; Brautigan DL; Paschal BM
    Mol Cell Biol; 2007 May; 27(9):3390-404. PubMed ID: 17325038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.